Union Health Ministry Proposes Immediate Suspension of Manufacturing Licences for Drugs Found Not of Standard Quality on Specified Critical Parameters

The Union Health Ministry proposes immediate suspension of a drug’s manufacturing licence when a Government Analyst declares it Not of Standard Quality on specified critical parameters. The goal is rapid intervention. It would reduce the time during which a potentially risky medicine could continue being made or distributed.

The proposed action applies to failures involving assay, dissolution, related substances, impurities, or sterility. For example, if a Government Analyst reports that a medicine fails its sterility test, the Central Licensing Approving Authority or State Licensing Authority could suspend the licence immediately.

The licence would remain suspended until the manufacturer completes a root-cause analysis and implements effective Corrective and Preventive Action. The relevant Licensing Authority must verify those measures before restoring the licence. The proposal follows DCC and DTAB deliberations and is intended to strengthen post-marketing surveillance.

“Not of Standard Quality,” or NSQ, is the regulatory finding used when a drug does not meet prescribed quality standards. In this proposal, the relevant finding comes from a Government Analyst’s report. The article connects NSQ action specifically with failures in assay, dissolution, related substances, impurities, or sterility.

For example, a Government Analyst may test a medicine and report that its assay does not meet the required standard. That drug would be declared NSQ for that parameter. The proposed rules would then allow the concerned licensing authority to suspend its manufacturing licence immediately.

NSQ does not automatically describe every possible defect under this proposed mechanism. It identifies a quality failure covered by the report and the specified parameters. The manufacturer must investigate the root cause, complete suitable Corrective and Preventive Action, and obtain verification before suspension can be revoked.

The proposal identifies five critical quality parameters that can trigger immediate suspension of a manufacturing licence. They are assay, dissolution, related substances, impurities, and sterility. The Ministry describes these parameters as critical to determining medicine quality.

For example, a Government Analyst’s report declaring a drug NSQ because of impurities would qualify for the proposed immediate action. The same mechanism would apply if the reported failure involved assay, dissolution, related substances, or sterility. The specific test result would be communicated to relevant regulators and the manufacturer and marketer.

The proposal does not set out numerical limits for these tests in the article. It focuses instead on the regulatory consequence of an NSQ finding on any listed parameter. The aim is to minimise potential patient risks, stop continued manufacture and distribution, and support coordinated action across authorities.

After a Government Analyst reports that a drug is NSQ for assay, dissolution, related substances, impurities, or sterility, the proposed rules would permit immediate suspension of the concerned manufacturing licence. This is faster than waiting for the existing procedure to run its course.

The suspension would prevent the manufacturer from continuing the relevant activity while the quality problem is addressed. The manufacturer would need to undertake an effective Root Cause Analysis. It would then have to implement appropriate Corrective and Preventive Action, or CAPA, to the satisfaction of the concerned Licensing Authority.

Suspension would not be revoked simply because the manufacturer promises to act. The Licensing Authority must verify that the required measures have been implemented. Only after that verification would restoration be permitted. The approach is intended to address the failure and reduce the chance of recurrence.

The proposed authority depends on the applicable licensing arrangement. The Central Licensing Approving Authority or the State Licensing Authority, as the case may be, can immediately suspend the manufacturing licence after receiving a qualifying Government Analyst’s NSQ report.

The proposed amendments would also change Form 13, which concerns the Government Analyst’s test report. The report would be endorsed to the Drugs Controller General of India, or DCGI, and to the concerned State or Union Territory Licensing Authority where the manufacturing site is located.

The manufacturer and marketer of the concerned drug would receive the report as well. This wider circulation is intended to support timely communication, coordinated regulatory action, and accountability across the drug manufacturing and marketing chain. The article does not assign a personal name to the DCGI or identify individual licence holders.

Under the existing Drugs Rules, 1945, suspension or cancellation of a manufacturing licence is preceded by prescribed regulatory procedures, including a show-cause notice. These steps are intended to provide due process before regulatory action. However, they can take time after a drug is declared NSQ.

During that time gap, the concerned drug may continue to be manufactured, distributed, or remain in circulation. The article warns that this can pose potential risks to public health. It can also make an effective recall more difficult because the medicine may already have reached more locations.

The proposed immediate-suspension provision is meant to close that gap for failures involving the five listed critical parameters. It would allow the appropriate licensing authority to act upon receipt of the Government Analyst’s report, while keeping restoration conditional on root-cause analysis, CAPA, and verification.

Assay concerns the medicine’s measured amount of active substance, while dissolution concerns how it releases for use. Related substances and impurities indicate unwanted chemical components, and sterility concerns freedom from microbial contamination. In general, failures can affect a medicine’s effectiveness or safety. The article identifies all five as critical quality parameters.

For example, a batch with an impurity failure may be declared NSQ by a Government Analyst. The manufacturer must then investigate why the failure occurred through Root Cause Analysis. It must implement Corrective and Preventive Action, or CAPA, addressing the identified problem and adding safeguards against recurrence.

The licence is not restored merely because action is promised. The concerned Licensing Authority must be satisfied that effective measures were implemented and must verify them. This condition links regulatory relief to evidence that the quality deficiency was addressed and future risks reduced.